A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

Rhinoconjunctivitis Clinical Trial

Official title:

A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02477917
• Other study ID #: BIA-PAR-DEPOT
• Status: Completed
• Phase: Phase 1
• First received: June 1, 2015
• Last updated: April 28, 2017
• Start date: May 2015
• Est. completion date: March 2016

Study information

• Verified date: April 2017
• Source: Roxall Medicina España S.A
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Parietaria judaica pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity.

Description:

Parietaria judaica is a weed widespread throughout the Mediterranean área. Prevalence of sensitization to Parietaria judaica's pollen is very high in the Mediterranean areas, reaching 41.4% among allergic patients on the Spanish Mediterranean coast.

The study has been designed as an open trial which will be conducted in 4 Spanish sites.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients must sign the informed consent form.

2. Patients must be between 18 and 60 years of age.

3. Patients with seasonal allergic rhinoconjunctivitis against Parietaria judaica during a minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild concomitant asthma is allowed (GINA 2013).

4. Patients who obtained a prick test result = 3 mm diameter to Parietaria judacia. Positive and negative control of the test should give consistent results.

5. Patients with specific immunoglobulin E = class 2 (CAP/PHADIA) to Parietaria judaica.

6. Patients sensitized to Parietaria judaica with clinically relevant symptoms in which treatment with Parietaria judaica 100% vaccine is indicated.

7. Women of childbearing potential must have a negative urine pregnancy test at Screening visit/Visit 0.

8. Women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active.

Exclusion Criteria:

1. Patients who received immunotherapy in the previous 5 years for Parietaria judaica or fo rany allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.

2. Patients with severe asthma or forzed expiratoy volumen in 1 second FEV1< 70% even if the are pharmacologically controlled .

3. Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.

4. Patients with a previous history of anaphylaxis

5. Patients with chronic urticaria,

6. Patients with moderate to severe atopic dermatitis

7. Patients who have participated in another clinical trial within 3 month prior to enrolment.

8. Patients under treatment with tricyclic antidepressives, phenothiazines , ß-blockers, or Angiotensin Converting Enzyme Inhibitors (ACEI)

9. Female patients who are pregnant or breast-feeding

10. Patient who does not attend the visits

11. Patient's lack of collaboration or refusal to participate.

Related Conditions & MeSH terms

• Conjunctivitis
• Rhinoconjunctivitis

Intervention

Biological:
• Allergovac depot with Parietaria judaica pollen extract
Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections

Locations

Country	Name	City	State
Spain	Hospital de Manises	Manises	Valencia
Spain	Hospital Vega Baja	Orihuela	Alicante
Spain	Hosptal de Sagunto	Sagunto	Valencia
Spain	Hospital Universitario y Politécnico La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Roxall Medicina España S.A

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and severity of adverse reactions as a measure of Safety and tolerability		across 17 weeks treatment period
Secondary	Immunoglobulin changes from baseline		At baseline and 1 week after last administered dose
Secondary	Skin reactivity changes from baseline		At baseline and 1 week after last administered dose